A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016

Reference

1. 1.↵
   1. Denyer S. P.,
   2. Hodges N. A.,
   3. Gorman S. P.

   1. Baird R.

   Microbial Spoilage, Infection Risk and Contamination Control. In Hugo and Russell's Pharmaceutical Microbiology; Denyer S. P., Hodges N. A., Gorman S. P., Eds., 7th ed; Blackwell: Malden, MA, 2004; Vol. 16, pp 263–284.

   OpenUrl
2. 2.↵
   1. Grady D.

   The Epidemiology of Drug Recalls. American Medical Association 2012, 172 (14), 1109–1110.

   OpenUrl
3. 3.↵
   1. Sutton S.,
   2. Jimenez L. A.

   Review of Reported Recalls Involving Microbiological Control 2004–2011 with Emphasis on FDA Considerations of “Objectionable Organisms”. Am. Pharm. Rev. 2012, 15 (1), 1–12.

   OpenUrl
4. 4.↵
   1. Cheah E. T.,
   2. Chan W. Li.,
   3. Chieng C. L.

   L. The Corporate Social Responsibility of Pharmaceutical Product Recalls: An Empirical Examination of U.S. and U.K. Markets. J. Business Ethics 2007, 76 (4), 427–449.

   OpenUrl
5. 5.↵
   1. Stewart K. L.,
   2. Whiton S. P.

   Johnson and Johnson: An Ethical Analysis of Broken Trust. J. Academic and Business Ethics 2012, 5 (7), 1–10.

   OpenUrl
6. 6.↵
   EMA. EudraGMDP. European Medicines Agency. http://eudragmdp.ema.europa.eu/inspections/logonGeneralPublic.do.
7. 7.↵
   FDA. Warning Letters. US Food and Drug Administration. http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/.
8. 8.↵
   1. Banaitiene N.

   1. Botet J.

   Quality Risk Analysis: Value for Money in the Pharmaceutical Industry. In Risk Management—Current Issues and Challenges; Banaitiene N., Ed.; InTech: Rijeka, Croatia, 2012; Vol. 17, pp 388–410.

   OpenUrl
9. 9.↵
   1. O'Donnell K.

   QRM in the GMP Environment: Ten Years On—Are Medicines Any Safer Now? A Regulators Perspective. Institute Validation Technol. 2015, 21 (4), 1–12.

   OpenUrl
10. 10.↵
    European Commission. EU Pharmaceutical Information. European Commission. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm.
11. 11.↵
    1. Waldron K.

    Risk Analysis and Ordinal Risk Rating Scales—A Closer Look. Institute of Validation Technol. 2015, 21 (6), 1–6.

    OpenUrl
12. 12.↵
    1. Ishikawa K.

    Guide to Quality Control—Industrial Engineering and Technology, 2nd ed.; Asian Productivity Organization: Tokyo, Japan, 1976.
13. 13.↵
    ICH Q9. Quality Risk Management. ICH Harmonized Tripartite Guideline. November 2005. http://www.ich.org.
14. 14.↵
    IEC. IEC/ISO 31010—Risk Management—Risk Assessment Techniques. International Electrotechnical Commission: Geneva, 2008.
15. 15.↵
    WHO. WHO Guideline on Quality Risk Management. World Health Organization. October 2010. http://www.who.int/medicines/areas/quality_safety/quality_assurance/QualityRiskManagement_QAS10-376Rev2_27082012.pdf.
16. 16.↵
    INFARMED. Acordos de Colaboração. INFARMED Autoridade Nacional do Medicamento e Produtos de saúde. http://www.infarmed.pt/portal/page/portal/SOBRE_O_INFARMED/RELACOES_INTERNACIONAIS/ACORDOS/Acordo%20Parceria%2023_Jan_2014.pdf.
17. 17.↵
    United States Pharmacopeia (USP). USP <1115> Bioburden Control of Nonsterile Drug Substances and Products. USP 38—NF33; United States Pharmacopeial Convention: Rockville, MD, 2015; p 1185.
18. 18.↵
    ICH Q6A. Specification: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products Chemical Substances. ICH. ICH Harmonized Tripartite Guideline, October 1999. http://www.ich.org.
19. 19.↵
    1. Sutton S.

    The Importance of Microbiology in the Contamination Control Plan for Aseptic, Terminally Sterilized and Non-sterile Manufacturing. Pharm. Microbiol. Forum Newsletter 2007, 13 (6), 3–5.

    OpenUrl
20. 20.↵
    FDA. Guidance for Industry—Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production. October 2006. http://www.fda.gov/downloads/drugs/guidances/ucm070287.pdf.
21. 21.↵
    FDA. Guidance for Industry—Contract Manufacturing Arrangements for Drugs: Quality Agreements. November 2016. http://www.fda.gov/downloads/drugs/guidances/ucm353925.pdf.
22. 22.↵
    FDA. Enforcement Reports. US Food and Drug Administration. http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm.
23. 23.↵
    1. Guilfoyle D. E.,
    2. Friedman R. L.,
    3. Hughes P. F.,
    4. Hussong D.,
    5. Rosenberg A. S.,
    6. Brorson K.

    Microbial Risk in Pharmaceutical Manufacturing and ICH Q9. PDA J. Pharm. Sci. Technol. 2013, 67 (2), 79–81.

    OpenUrlFREE Full Text
24. 24.↵
    1. Sutton S.

    How to Determine If an Organism Is “Objectionable”. Pharm. Microbiology Forum Newsletter 2006, 12 (7), 2–9.

    OpenUrl